Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells

Biochemical and Biophysical Research Communications

Volumn 435, Issue 3, 2013, Pages 506-511

  Okabe, Seiichi ^a   Tauchi, Tetsuzo ^a   Tanaka, Yuko ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

ABL kinase inhibitor resistance; Point mutation; Ponatinib

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CRK LIKE PROTEIN; IMATINIB; NILOTINIB; PONATINIB; PROTEIN KINASE LYN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDAZINES;

EID: 84878967519     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.05.022     Document Type: Article

References (12)

1. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N. Engl. J. Med. 1999, 341:164-172.
2. Chu S., Li L., Singh H., Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res. 2007, 67:7045-7053.
3. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S.G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M., Morra E. International STI571 CML study group, hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002, 346:645-652.
4. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8:1018-1029.
5. Jabbour E., Deininger M., Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011, 25:201-210.
6. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., Adrian L.T., Zhou T., Huang W.S., Xu Q., Metcalf C.A., Tyner J.W., Loriaux M.M., Corbin A.S., Wardwell S., Ning Y., Keats J.A., Sundaramoorthi R., Thomas M., Zhou D., Snodgrass J., Commodore L., Sawyer T.K., Dalgarno D.C., Deininger M.W., Druker B.J., Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
7. O'Hare T., Deininger M.W., Eide C.A., Clackson T., Druker B.J. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin. Cancer Res. 2011, 17:212-221.
8. Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., Yokota A., Kamitsuji Y., Kawata E., Ashihara E., Nakaya Y., Naruoka H., Wakayama T., Nasu K., Asaki T., Niwa T., Hirabayashi K., Maekawa T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948-3954.
9. Okabe S., Tauchi T., Tanaka Y., Ohyashiki K. Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. J. Hematol. Oncol. 2011, 4:32.
10. Okabe S., Tauchi T., Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann. Hematol. 2010, 89:1081-1087.
11. Okabe S., Tauchi T., Tanaka Y., Katagiri S., Ohyashiki K. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Stem Cells Dev. 2012, 21(21):2939-2948.
12. Jabbour E., Hochhaus A., Cortes J., La Rosée P., Kantarjian H.M. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010, 24:6-12.